Latest Options News

Dalrymple Bay Infrastructure Limited reported robust FY-24 results, announcing a 3.6% rise in terminal charges and a 6.5% increase in distribution guidance, underpinned by a $394 million capital investment program.

Nufarm reported a mixed 1H25 result with a strong rebound in crop protection profits contrasting a steep decline in seed technologies earnings, prompting a strategic review of the latter business.

Duketon Mining has advanced exploration activities at its Killarney and Barlee gold projects, with new sampling and drilling programs underway pending approvals.

James Hardie has released its financial results for the fourth quarter and full year ended March 31, 2025, accompanied by a suite of detailed reports filed with both the ASX and SEC.

Macarthur Minerals has secured $250,000 through unsecured convertible notes to bolster its working capital and support ongoing operations amid challenging market conditions.

WAM Strategic Value Limited has updated its interim dividend and Dividend Reinvestment Plan details for the six months ending December 2024, confirming a fully franked dividend of 3 cents per share payable in late May.

Merino & Co has amended its quarterly report to correct expenditure figures and clarify related party payments, while reporting significant operational progress including new product launches and cryptocurrency integration.

Terrain Minerals has kicked off a 3,350-meter drilling campaign at its Lightning and Monza prospects, aiming to expand on recent high-grade gold and silver discoveries. Concurrently, the company has opened a $1.8 million rights issue to fund ongoing exploration and development.

Chimeric Therapeutics has raised $6.6 million through a discounted two-tranche placement to accelerate its promising CAR-T and NK cell therapy clinical programs. The capital raise, strongly backed by institutional and professional investors, signals growing confidence in the company’s oncology pipeline.

Clarity Pharmaceuticals has initiated its second registrational Phase III AMPLIFY trial for the Cu-SAR-bisPSMA PET imaging agent targeting biochemical recurrence of prostate cancer. The multi-centre study aims to generate critical data supporting FDA approval and could redefine prostate cancer diagnostics.

Atomo Diagnostics has released a Target Market Determination for a new capital raising involving options and shares, including a $1 million Share Purchase Plan and placement offer. The move targets eligible Australian shareholders and aims to bolster the company’s financial position amid a speculative investment environment.

Atomo Diagnostics Limited has announced a capital raising initiative comprising a Share Purchase Plan (SPP) and a Placement, aiming to raise up to $1 million through the SPP and additional funds via a Placement, subject to shareholder approval at a June 23 meeting.